blv

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:

• Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
• HBV cure from the Everest Project in China
• HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
• HCV retreatment in patients with prior direct-acting antiviral therapy failure

Presenter: 

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD

Link to full program: 
https://bit.ly/3AjCNBC

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:

• Novel therapeutics for HBV
• Therapeutic vaccination for HBV
• Emerging treatment options for HDV
• HCV care cascade
• HCC monitoring after HCV cure

Presenter: 

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Follow along with the downloadable slideset at: 
https://bit.ly/3yJAruD

Link to full program:
https://bit.ly/3IeUapm

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from AASLD 2021, including:

• HBV treatment in pregnancy
• Outcomes following HBV treatment withdrawal  
• Progress toward an HBV cure
• HCV implementation science and current status of the cascade of care
• Hepatitis delta virus: understanding the clinical impact
• Phase III clinical trial updates for hepatitis delta virus, including data on bulevirtide

Presenter:  

Nancy Reau, MD
Professor of Medicine  
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Follow along with the downloadable slideset at:
https://bit.ly/3d6NQRV

Link to full program:
https://bit.ly/3lputrT